PMID: 7021413May 1, 1981Paper

Mechanism of acid-activation of renin: role of kallikrein in renin activation

Hypertension
W A HsuehM Israel-Hagman

Abstract

Dialysis of plasma in pH 3.3 and then pH 7.5 is a method commonly used to activate plasma inactive renin. Endogenous plasma kallikrein has been shown to participate in activation during neutral dialysis. The present studies demonstrate that plasma inactive renin is fully activated following dialysis to pH 3.3 at 10 degrees C. Activation by low pH is a reversible process when followed by titration to a pH greater than 4.0. The rate of reversal of acid activation increases with increasing pH and temperature, reaching a maximum at pH 7.0 ad 37 degrees C. the disappearance of activated renin is not due to its destruction, because dialysis back to pH 3.3 fully restores activation. A preparation of renin zymogen devoid of active renin also shows complete reversal of activation. The Km of acid-activated renin is the same as that of endogenous active renin. Acid-activated renin (untreated by protease) elutes with an apparently greater Stokes radius than non-acid-treated inactive renin on Sephadex G-100. Once reversal of acid activation occurs, renal or plasma kallikrein has no effect on renin. However, once kallikrein acts on acid-activated renin, activation is no longer reversible. These data can explain the mechanism of acid activati...Continue Reading

References

Jul 1, 1978·Clinical Science and Molecular Medicine·A A ShulkesS L Skinner
Jan 1, 1979·Methods in Enzymology·K F Tipton, H B Dixon
Nov 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·J E SealeyA P Kaplan
Oct 16, 1976·Lancet
Sep 4, 1976·Lancet·F H DerkxM A Schalekamp
Nov 1, 1979·The Journal of Clinical Endocrinology and Metabolism·A M HedlinD H Osmond
Jun 1, 1975·The Journal of Clinical Endocrinology and Metabolism·R P Day, J A Luetscher
Feb 1, 1975·The Australian Journal of Experimental Biology and Medical Science·S L SkinnerN H Fidge
Jul 1, 1978·The Journal of Clinical Endocrinology and Metabolism·E E Slater, E Haber
Feb 1, 1979·Clinical Science·F H DerkxM A Schalekamp
Nov 1, 1976·Proceedings of the National Academy of Sciences of the United States of America·H Neurath, K A Walsh
May 1, 1974·The Journal of Clinical Endocrinology and Metabolism·R P Day, J A Luetscher
Sep 1, 1980·The Journal of Clinical Endocrinology and Metabolism·W A HsuehG Grislis
Jan 1, 1980·Endocrine Reviews·J E SealeyJ H Laragh
Oct 1, 1980·The Journal of Clinical Endocrinology and Metabolism·W A HsuehS Warren
Jan 1, 1980·Clinical and Experimental Hypertension : CHE·F H DerkxM A Schalekamp
Feb 27, 1980·Biochimica Et Biophysica Acta·B Aasted

❮ Previous
Next ❯

Citations

Jan 1, 1983·Clinical and Experimental Hypertension. Part A, Theory and Practice·M KawamuraM Ikeda
Jan 1, 1987·Clinical and Experimental Hypertension. Part A, Theory and Practice·J E SealeyJ H Laragh
Jan 1, 1982·Clinical and Experimental Hypertension. Part A, Theory and Practice·F X GalenP Corvol
Jan 1, 1982·Clinical and Experimental Hypertension. Part A, Theory and Practice·E J Leckie
Jan 1, 1982·Clinical and Experimental Hypertension. Part A, Theory and Practice·W A Hsueh, E J Carlson
Jan 1, 1982·Clinical and Experimental Hypertension. Part A, Theory and Practice·F H DerkxM A Schalekamp
Jan 1, 1982·Clinical and Experimental Hypertension. Part A, Theory and Practice·B Leckie
Jan 1, 1982·Clinical and Experimental Hypertension. Part A, Theory and Practice·J A LuetscherG Grislis
Dec 1, 1988·American Journal of Obstetrics and Gynecology·R J PaulsonR A Lobo
Jan 1, 1986·Kidney International·A G Scicli, O A Carretero
Sep 1, 1992·Trends in Endocrinology and Metabolism : TEM·J M Halimi, J E Sealey
Dec 1, 1986·The American Journal of Medicine·J E SealeyJ H Laragh
Nov 1, 2012·Biochemical and Biophysical Research Communications·A H M Nurun NabiFumiaki Suzuki
Jan 1, 1987·British Journal of Obstetrics and Gynaecology·F H DerkxM A Schalekamp
Nov 15, 1985·Biochemical and Biophysical Research Communications·S A AtlasL C Fritz
Sep 1, 1991·Hypertension·T Inagami
Apr 1, 1991·Hypertension·W A Hsueh, J D Baxter
Apr 14, 1988·Biochimica Et Biophysica Acta·D A EganP A Marcotte
Jul 3, 2021·The FEBS Journal·Yong Juan ZhaoDapeng Zhang

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.